Top Oxycodone Brands You Should Know About

Oxycodone, a potent opioid pain medication, is available through a variety of reputable pharmaceutical brands that ensure both quality and efficacy. Some of the leading brands that produce oxycodone include OxyContin, Roxicodone, and OxyIR, each offering different formulations to cater to various therapeutic needs. These brands are well-regarded for their stringent manufacturing standards and have been trusted by healthcare providers for effective pain management. To learn more about these brands and how they compare, please see the detailed information provided below.

Illustration of oxycodone

Best brands of oxycodone in 2025

OxyContin

OxyContin, manufactured by Purdue Pharma, was a leading brand in the oxycodone market, particularly notable for its controlled-release formulation approved by the FDA in 1995. By 2001, OxyContin had become the most frequently prescribed brand-name narcotic medication for treating moderate-to-severe pain, with sales exceeding $1 billion annually. Despite its small market share, never exceeding 4% of the total prescription opioid market, OxyContin had a significant impact, especially in certain states where it dominated the opioid market, such as Rhode Island and Connecticut. The reformulated version of OxyContin, introduced in 2010, included physicochemical barriers to tampering, which reduced its street value and abuse potential. However, the original formulation's aggressive marketing and widespread prescription contributed to its abuse and diversion issues. For more detailed insights, you can visit the study on OxyContin's impact.

Roxicodone

Roxicodone, a brand of oxycodone hydrochloride tablets, is known for its high oral bioavailability, with 60% to 87% of the oral dose reaching systemic circulation, making it one of the most effective immediate-release oxycodone products. The tablets are bioequivalent across different strengths, such as 5 mg, 15 mg, and 30 mg, ensuring consistent pharmacokinetics. Roxicodone reaches steady-state plasma concentrations in approximately 18 to 24 hours and has an elimination half-life of 3.5 to 4 hours. The product's design and pharmacokinetic profile make it a reliable choice for managing moderate to severe pain. Additionally, food intake can enhance the extent of oxycodone absorption by up to 27% but does not affect the rate of absorption. For more detailed information, you can review the FDA labeling document.

Xtampza ER

Xtampza ER, an oxycodone-based extended-release medication, stands out as a leading option for managing severe and persistent pain, holding a market share of 25.1% in the oxycodone extended-release market as of December 2020, up from 18.9% in December 2019. It is notable for its lower rates of nonmedical use (NMU) compared to other oxycodone ER and IR products, with NMU rates significantly lower in a population seeking substance abuse treatment. Xtampza ER provides up to 12 hours of pain relief per dose, reducing the need for frequent dosing. The medication is designed to be taken with food and offers flexible administration options, including the ability to be taken in various forms if swallowing pills is difficult. Its abuse-deterrent formulation has been evaluated in clinical studies, showing lower preference for crushed or manipulated forms compared to immediate-release oxycodone.

OxyIR

OxyIR is a prominent brand for oxycodone, known for its immediate-release formulations that offer high bioavailability, ranging from 60 to 87%. This brand provides effective pain management with a rapid onset of action, typically within 10-30 minutes, and a duration of action lasting 3-6 hours. Oxycodone from OxyIR is extensively metabolized in the liver, primarily by CYP3A, and is excreted mainly through urine (83%). The drug's efficacy is largely attributed to the parent compound itself, which accounts for 83.0% and 94.8% of its analgesic effect following oral and intravenous administration, respectively. Introduced as part of the broader oxycodone market, OxyIR has been a significant player since its approval, particularly noted for its use in managing moderate-to-severe pain. For more detailed information, visit the Oxycodone Wikipedia page.

Oxecta

Oxecta, developed by Pfizer and Acura Pharmaceuticals, is a notable brand for oxycodone, particularly distinguished by its abuse-deterrent formulation. Approved by the FDA on June 17, 2011, Oxecta is designed to manage acute and chronic moderate to severe pain using immediate-release oxycodone HCl tablets. The product incorporates AVERSION® Technology to discourage common methods of tampering associated with opioid abuse. Available in 5 mg and 7.5 mg strengths, Oxecta is contraindicated in patients with respiratory depression, paralytic ileus, and acute or severe bronchial asthma. Despite its discontinuation, Oxecta remains a significant example of innovative approaches to opioid formulation. For more detailed information, visit the Oxecta information page.

Endocodone

Endocodone, while not specifically mentioned as a brand in the provided sources, is often associated with oxycodone products due to its similarity in name. However, for accurate information, brands like OxyContin by Purdue Pharma are well-documented. OxyContin, introduced in 1996, quickly became the most prescribed brand-name narcotic medication for treating moderate-to-severe pain by 2001, with sales exceeding $1 billion annually. It offers continuous relief from pain over a 12-hour period and has a bioavailability of 60% to 87% when taken orally. The drug is metabolized by enzymes CYP3A4 and CYP2D6, and its peak plasma levels occur within 3 hours for extended-release formulations. For detailed information regarding oxycodone, you can refer to the Mayo Clinic resource.

Dazidox

Dazidox, while not the most highly rated, is a brand that produces oxycodone, a potent opioid analgesic with a high oral bioavailability of up to 87% and a half-life of around 3.2 to 4.5 hours depending on the formulation. Oxycodone from Dazidox is used for managing severe pain and has various pharmacological effects, including respiratory depression and constipation. However, it has a lower user satisfaction rating compared to other oxycodone products, with only 20% of reviewers reporting a positive effect on Drugs.com. The drug is metabolized extensively by the liver, primarily through CYP3A4 and CYP2D6 enzymes. Despite its lower ratings, Dazidox oxycodone is still a recognized product in the market. For more detailed information about Dazidox oxycodone, you can refer to DrugBank.

Roxybond

RoxyBond, developed by Inspirion Delivery Sciences LLC, is a groundbreaking immediate-release oxycodone hydrochloride tablet approved by the FDA in 2017 for managing severe pain. It is the first and only immediate-release opioid analgesic with approved abuse-deterrent label claims, utilizing physical and chemical barriers to deter misuse. RoxyBond demonstrated higher resistance to cutting, crushing, grinding, and breaking, as well as resistance to extraction in various solvents, reducing the potential for intranasal and IV abuse. The FDA's advisory committees voted 19 to 0, with one abstention, to recommend its approval. Available in 5 mg, 15 mg, and 30 mg dosages, RoxyBond offers a significant advancement in the fight against opioid abuse. For more detailed information, you can view the FDA's full approval document.

Eth-Oxydose

Eth-Oxydose, a brand of oxycodone, is recognized for its effective pain relief in cases where other medications are insufficient or not tolerated. It is available in various formulations, including immediate and extended-release options, to cater to different patient needs. Common side effects include nausea (23% to 27%), constipation (23% to 26%), and vomiting (12% to 14%). The medication requires careful administration, especially during initiation and dose increases, due to the risk of respiratory depression and other serious side effects. Accidental ingestion, particularly by children, can be fatal, highlighting the need for strict handling and storage. For more details on Eth-Oxydose side effects, visit their comprehensive guide online.

Oxylan

Oxylan, a brand known for its high-quality oxycodone formulations, is renowned for its prolonged-release tablets designed to treat severe pain. Each Oxylan tablet contains oxycodone hydrochloride, with strengths ranging from 5 mg to 80 mg, corresponding to 4.48 mg to 71.72 mg of oxycodone, respectively. The tablets are formulated to provide controlled delivery over 12 hours, ensuring steady-state plasma concentrations are achieved within 24-36 hours. Oxylan's bioavailability is notable, with oral bioavailability ranging from 60% to 87%, similar to other trusted formulations like OxyContin. The tablets are manufactured with strict quality control, adhering to European Pharmacopoeia standards. For more detailed information, you can access the patient information leaflet.